In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex.
AUTOR(ES)
Meyer, S C
RESUMO
PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite were evaluated for in vitro activity against 31 clinical Mycobacterium avium complex isolates. Broth dilution MICs of PS-15 ranged from 16 to 64 micrograms/ml. The cyclic metabolite was three to five times more active than the parent compound. Further evaluation of these compounds in an M. avium-infected murine test system will be of interest.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162841Documentos Relacionados
- In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.
- Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.
- Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.
- In Vitro Activities of Several Diaminomethylpyridopyrimidines against Mycobacterium avium Complex
- In vitro activities of the biguanide PS-15 and its metabolite, WR99210, against cycloguanil-resistant Plasmodium falciparum isolates from Thailand.
